Skip to content
PubMed This is a summary of 69 peer-reviewed journal articles Updated

Research & Literature

Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.

Explore the Literature Visualize citation networks across 69 referenced papers

Top Authors

Jason R. Gotlib
Stanford Medicine
Andreas Reiter
Heidelberg University
Nicholas C.P. Cross
University of Southampton
Daniel A. Arber
University of Chicago
Attilio Orazi
Texas Tech University Health Sciences Center
Sa A. Wang
The University of Texas MD Anderson Cancer Center
Georgia Metzgeroth
Heidelberg University
Nicole Naumann
Heidelberg University
Naveen Pemmaraju
The University of Texas MD Anderson Cancer Center
Robert Paul Hasserjian
Massachusetts General Hospital

Top Institutions

Ranked by publications Top 10 institutions
05

University of Southampton

Southampton, United Kingdom

24 papers
08

Texas Tech University Health Sciences Center

Lubbock, United States

17 papers
Contributors Attilio Orazi

References

References (69)
  1. 1

    Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.

    Gotlib J

    Current hematologic malignancy reports 2015; (10(4)):351-61 doi:10.1007/s11899-015-0280-3.

    PMID: 26404639
  2. 2

    Hypereosinophilic syndrome: cardiac diagnosis and management.

    Mankad R, Bonnichsen C, Mankad S

    Heart (British Cardiac Society) 2016; (102(2)):100-6 doi:10.1136/heartjnl-2015-307959.

    PMID: 26567231
  3. 3

    BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.

    He R, Greipp PT, Rangan A, et al.

    Cancer genetics 2016; (209(5)):223-8.

    PMID: 27134074
  4. 4

    Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

    Pemmaraju N, Gupta V, Thompson MA, Lane AA

    Current hematologic malignancy reports 2016; (11(6)):462-467 doi:10.1007/s11899-016-0340-3.

    PMID: 27492117
  5. 5

    Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety".

    Bauml JM, Troxel A, Epperson CN, et al.

    Lung cancer (Amsterdam, Netherlands) 2016; (100()):110-113 doi:10.1016/j.lungcan.2016.08.002.

    PMID: 27597289
  6. 6

    Myeloid neoplasms with eosinophilia.

    Reiter A, Gotlib J

    Blood 2017; (129(6)):704-714 doi:10.1182/blood-2016-10-695973.

    PMID: 28028030
  7. 7

    Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.

    Tang G, Sydney Sir Philip JK, Weinberg O, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019; (32(4)):490-498 doi:10.1038/s41379-018-0165-9.

    PMID: 30401948
  8. 8

    Idiopathic Hypereosinophilic Syndrome in an Elderly Female: A Case Report.

    Khalid F, Holguin F

    The American journal of case reports 2019; (20()):381-384 doi:10.12659/AJCR.912747.

    PMID: 30902963
  9. 9

    A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease.

    Diamond EL, Reiner AS, Buthorn JJ, et al.

    Blood advances 2019; (3(7)):934-938 doi:10.1182/bloodadvances.2018030502.

    PMID: 30917949
  10. 10

    World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.

    Shomali W, Gotlib J

    American journal of hematology 2019; (94(10)):1149-1167 doi:10.1002/ajh.25617.

    PMID: 31423623
  11. 11

    [Myeloid/lymphoid neoplasms with eosinophilia and FGFR1 rearrangement: 5 cases report and literatures review].

    Liu YT, Zhao JW, Feng J, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2019; (40(10)):848-852 doi:10.3760/cma.j.issn.0253-2727.2019.10.010.

    PMID: 31775485
  12. 12

    Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.

    Al-Ali HK, Griesshammer M, Foltz L, et al.

    British journal of haematology 2020; (189(5)):888-903 doi:10.1111/bjh.16462.

    PMID: 32017044
  13. 13

    The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and ZBTB20-JAK2 gene fusion presenting as B-lymphoblastic leukemia.

    Lee WY, Pfau RB, Choi SM, et al.

    Cold Spring Harbor molecular case studies 2020; (6(2)) doi:10.1101/mcs.a004937.

    PMID: 32238402
  14. 14

    Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.

    Schwaab J, Naumann N, Luebke J, et al.

    American journal of hematology 2020; (95(7)):824-833 doi:10.1002/ajh.25825.

    PMID: 32279331
  15. 15

    Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia.

    Snider JS, Znoyko I, Lindsey KG, et al.

    Cancer genetics 2020; (246-247()):44-47 doi:10.1016/j.cancergen.2020.08.004.

    PMID: 32827877
  16. 16

    Loeffler's Endocarditis: An Integrated Multimodality Approach.

    Polito MV, Hagendorff A, Citro R, et al.

    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2020; (33(12)):1427-1441 doi:10.1016/j.echo.2020.09.002.

    PMID: 33129649
  17. 17

    Identification of STRBP as a Novel JAK2 Fusion Partner Gene in a Young Adult With Philadelphia Chromosome-Like B-Lymphoblastic Leukemia.

    Zhang XY, Dai HP, Li Z, et al.

    Frontiers in oncology 2020; (10()):611467 doi:10.3389/fonc.2020.611467.

    PMID: 33505919
  18. 18

    Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information era.

    Pemmaraju N, Wilson NR, Clementi Doan T, et al.

    Leukemia & lymphoma 2021; (62(9)):2253-2260 doi:10.1080/10428194.2021.1901096.

    PMID: 33749512
  19. 19

    Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.

    Santoro M, Rotolo C, Accurso V, et al.

    Chemotherapy 2021; (66(3)):87-91 doi:10.1159/000515430.

    PMID: 33784668
  20. 20

    Scanxiety: a scoping review about scan-associated anxiety.

    Bui KT, Liang R, Kiely BE, et al.

    BMJ open 2021; (11(5)):e043215 doi:10.1136/bmjopen-2020-043215.

    PMID: 34039571
  21. 21

    Hypereosinophilic syndrome: considerations for the cardiologist.

    Bondue A, Carpentier C, Roufosse F

    Heart (British Cardiac Society) 2022; (108(3)):164-171 doi:10.1136/heartjnl-2020-317202.

    PMID: 34172539
  22. 22

    Normalization of left ventricular filling pressure after cardiac surgery for the Loeffler's endocarditis: a case report.

    Carcaterra A, Mock S, Müller H, Testuz A

    European heart journal. Case reports 2021; (5(6)):ytab189 doi:10.1093/ehjcr/ytab189.

    PMID: 34263118
  23. 23

    Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics.

    Nann D, Fend F

    Cancers 2021; (13(14)) doi:10.3390/cancers13143528.

    PMID: 34298741
  24. 24

    Combined Ruxolitinib and Venetoclax Treatment in a Patient with a BCR-JAK2 Rearranged Myeloid Neoplasm.

    Lap CJ, Nassereddine S, Liu ML, et al.

    Case reports in hematology 2021; (2021()):2348977 doi:10.1155/2021/2348977.

    PMID: 34367701
  25. 25

    Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.

    Chen JA, Hou Y, Roskin KM, et al.

    Blood advances 2021; (5(17)):3492-3496 doi:10.1182/bloodadvances.2020004174.

    PMID: 34505882
  26. 26

    World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.

    Shomali W, Gotlib J

    American journal of hematology 2022; (97(1)):129-148 doi:10.1002/ajh.26352.

    PMID: 34533850
  27. 27

    Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

    Devos T, Selleslag D, Granacher N, et al.

    Hematology (Amsterdam, Netherlands) 2022; (27(1)):23-31 doi:10.1080/16078454.2021.2009645.

    PMID: 34957926
  28. 28

    Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia.

    Rizzuto G, Leoncin M, Imbergamo S, et al.

    Clinical case reports 2022; (10(1)):e05212 doi:10.1002/ccr3.5212.

    PMID: 35028141
  29. 29

    Contribution of imaging modalities to eosinophilic myocarditis diagnosis: a case report.

    Farhat N, Bouhabib M, Joye R, et al.

    European heart journal. Case reports 2022; (6(2)):ytac058 doi:10.1093/ehjcr/ytac058.

    PMID: 35295721
  30. 30

    Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies.

    Zhao Y, Chen P, Dou L, et al.

    Drug design, development and therapy 2022; (16()):817-825 doi:10.2147/DDDT.S354270.

    PMID: 35370398
  31. 31

    PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.

    Kaplan HG, Jin R, Bifulco CB, et al.

    The oncologist 2022; (27(8)):e661-e670 doi:10.1093/oncolo/oyac072.

    PMID: 35472244
  32. 32

    PCM1::JAK2 fusion associates with an atypical form of mycosis fungoides.

    Rodriguez-Sevilla JJ, Salido M, Rodriguez-Rivera M, et al.

    Virchows Archiv : an international journal of pathology 2022; (481(6)):967-973 doi:10.1007/s00428-022-03372-x.

    PMID: 35786767
  33. 33

    Updates on eosinophilic disorders.

    Tzankov A, Reichard KK, Hasserjian RP, et al.

    Virchows Archiv : an international journal of pathology 2023; (482(1)):85-97 doi:10.1007/s00428-022-03402-8.

    PMID: 36068374
  34. 34

    Two pediatric oncologic cases of hypereosinophilic syndrome and review of the literature.

    Voeller J, DeNapoli T, Griffin TC

    Cancer reports (Hoboken, N.J.) 2022; (5(11)):e1710 doi:10.1002/cnr2.1710.

    PMID: 36241191
  35. 35

    Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review.

    Houthuys JF, Wilmer AP, Peetermans M, et al.

    Heliyon 2022; (8(12)):e11782 doi:10.1016/j.heliyon.2022.e11782.

    PMID: 36478803
  36. 36

    Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.

    Lebon D, Dujardin A, Caulier A, et al.

    Leukemia research 2023; (125()):107005 doi:10.1016/j.leukres.2022.107005.

    PMID: 36580876
  37. 37

    Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.

    Zhang Y, Nguyen L, Lu CM, et al.

    Clinical lymphoma, myeloma & leukemia 2023; (23(3)):e150-e163 doi:10.1016/j.clml.2022.12.008.

    PMID: 36624015
  38. 38

    Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trial.

    El-Jawahri A, Luskin MR, Greer JA, et al.

    Cancer 2023; (129(7)):1075-1084 doi:10.1002/cncr.34645.

    PMID: 36655338
  39. 39

    Evaluation of myocardial performance by serial speckle tracking echocardiography in diagnosis and follow-up of a patient with eosinophilic myocarditis.

    Sharifkazemi M, Rezaian G, Lotfi M

    Echo research and practice 2023; (10(1)):1 doi:10.1186/s44156-022-00013-6.

    PMID: 36698163
  40. 40

    Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review.

    Zhang L, Shah B, Zhang Y, et al.

    Human pathology 2023; (136()):1-15 doi:10.1016/j.humpath.2023.03.002.

    PMID: 36958463
  41. 41

    Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study.

    Mascarenhas J, Nguyen H, Saunders A, et al.

    Future oncology (London, England) 2023; (19(11)):763-773 doi:10.2217/fon-2022-1298.

    PMID: 37161798
  42. 42

    Eosinophilic myocarditis: comprehensive update on pathophysiology, diagnosis, prognosis and management.

    Collini V, Burelli M, Favaretto V, et al.

    Minerva cardiology and angiology 2023; (71(5)):535-552 doi:10.23736/S2724-5683.23.06287-7.

    PMID: 37161920
  43. 43

    The international consensus classification of eosinophilic disorders and systemic mastocytosis.

    Wang SA, Orazi A, Gotlib J, et al.

    American journal of hematology 2023; (98(8)):1286-1306 doi:10.1002/ajh.26966.

    PMID: 37283522
  44. 44

    Rapid Hepatomegaly From Ruxolitinib Discontinuation Syndrome.

    van Rensburg RJ, Hale S, Calara A, et al.

    HCA healthcare journal of medicine 2023; (4(2)):199-204 doi:10.36518/2689-0216.1518.

    PMID: 37424984
  45. 45

    Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.

    Metzgeroth G, Steiner L, Naumann N, et al.

    Leukemia 2023; (37(9)):1860-1867 doi:10.1038/s41375-023-01958-1.

    PMID: 37454239
  46. 46

    Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases.

    Saft L, Kvasnicka HM, Boudova L, et al.

    Histopathology 2023; (83(6)):829-849 doi:10.1111/his.15021.

    PMID: 37551450
  47. 47

    Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24).

    Cai P, Liu S, Duan L, et al.

    Acta haematologica 2023; (146(5)):397-400 doi:10.1159/000510281.

    PMID: 37562364
  48. 48

    T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.

    Schoelinck J, Gervasoni J, Guillermin Y, et al.

    Virchows Archiv : an international journal of pathology 2024; (484(5)):853-857 doi:10.1007/s00428-023-03693-5.

    PMID: 37985498
  49. 49

    Hypereosinophilic syndrome associated with multiple thromboses requiring ICU admission: A case report.

    Ouanes I, Toumi S, Ben Cheikh Y, et al.

    La Tunisie medicale 2023; (101(10)):783-786.

    PMID: 38465762
  50. 50

    World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.

    Shomali W, Gotlib J

    American journal of hematology 2024; (99(5)):946-968 doi:10.1002/ajh.27287.

    PMID: 38551368
  51. 51

    How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.

    Reiter A, Metzgeroth G, Cross NCP

    Blood 2025; (145(16)):1758-1768 doi:10.1182/blood.2023022417.

    PMID: 39046810
  52. 52

    TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition.

    Lazarevic V, Lilljebjörn H, Olsson-Arvidsson L, et al.

    Genes, chromosomes & cancer 2024; (63(8)):e23261 doi:10.1002/gcc.23261.

    PMID: 39105620
  53. 53

    A chain mediation model reveals the association between metacognition and quality of life in hematologic tumor patients.

    Cheng C, Zheng M, Yan F, et al.

    Scientific reports 2024; (14(1)):18446 doi:10.1038/s41598-024-69027-w.

    PMID: 39117715
  54. 54

    Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta-analysis.

    Roca Mora MM, Afzal F, Guimaraes CR, et al.

    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2024; (132(11)):775-786 doi:10.1111/apm.13472.

    PMID: 39377511
  55. 55

    Next-generation sequencing RNA fusion panel for the diagnosis of haematological malignancies.

    Ngo TQ, Goh AFN, Dorwal P, et al.

    Pathology 2025; (57(3)):340-347 doi:10.1016/j.pathol.2024.09.009.

    PMID: 39672769
  56. 56

    A Case of Myeloproliferative Neoplasm with Eosinophilia Associated with PCM1-JAK2 Rearrangement.

    Zhou W, Guo X, Liu Y, et al.

    Case reports in oncology 2025; (18(1)):190-197 doi:10.1159/000542692.

    PMID: 39980500
  57. 57

    Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.

    Polverelli N, Hernández-Boluda JC, Onida F, et al.

    Blood 2025; (145(22)):2561-2573 doi:10.1182/blood.2024028000.

    PMID: 40106773
  58. 58

    Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review.

    Parasuraman S, Saverno K, Zimmerman Savill KM, Colucci P

    Acta haematologica 2026; (149(3)):252-262 doi:10.1159/000546910.

    PMID: 40618748
  59. 59

    Long-Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real-World Analysis.

    Blanco-Sánchez A, Ayala R, Carreño-Tarragona G, et al.

    EJHaem 2025; (6(6)):e70152 doi:10.1002/jha2.70152.

    PMID: 41169484
  60. 60

    Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes.

    Salmon M, Naumann N, Rinke J, et al.

    Leukemia 2026; (40(1)):37-46 doi:10.1038/s41375-025-02801-5.

    PMID: 41254115
  61. 61

    Loeffler Syndrome in FIP1L1-PDGFRA-Positive Myeloid Neoplasm.

    Alcalá Ramírez Del Puerto M, Sánchez Sánchez C, Piñero Uribe I, et al.

    JACC. Case reports 2026; (31(5)):106296 doi:10.1016/j.jaccas.2025.106296.

    PMID: 41379052
  62. 62

    JPOS/JASCC clinical guidelines for psychological distress in adult cancer patients: a summary of recommendations.

    Fujisawa D, Yoshikawa E, Fujimori M, et al.

    Japanese journal of clinical oncology 2026; (56(3)):324-336 doi:10.1093/jjco/hyaf209.

    PMID: 41459813
  63. 63

    Exploring psychological distress, appraisal, and coping during the scan result journey: a qualitative study of young and middle-aged Chinese adults with advanced cancer.

    Li X, Lu Y, Fan Y, et al.

    BMC cancer 2026; (26(1)).

    PMID: 41906115
  64. 64

    Psychological distress and quality of life in patients with indolent non-Hodgkin lymphoma.

    Kuiper JW, Custers JAE, Kleinjan A, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2026; (34(5)).

    PMID: 42082740
  65. 65

    Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (FIP1L1::PDGFRA) complicated by Loeffler's endocarditis leading to stroke.

    Luo R, Qi X

    BMC neurology 2026; (26(1)).

    PMID: 42135668
  66. 66

    Loeffler Endocarditis: Multimodality Imaging of a Common Cardiac Phenotype in Distinct Hypereosinophilic Syndromes.

    Salar T, Feitell S, Parikh V, Baibhav B

    JACC. Case reports 2026; (31(31)):108674 doi:10.1016/j.jaccas.2026.108674.

    PMID: 42301176
  67. 67

    Hypereosinophilic syndrome with Löffler endocarditis and multiple cerebral infarctions in a patient with a CLL-phenotype clonal B-cell population: a case report.

    Wang H, Zhu F, Hu H

    Frontiers in cardiovascular medicine 2026; (13()):1924869 doi:10.3389/fcvm.2026.1924869.

    PMID: 42688267
  68. 68

    Heart failure and predictors of outcome in eosinophilic myocarditis: a real-world cohort study.

    Ullrich FTH, Schönermarck U, Milger K, et al.

    Frontiers in medicine 2026; (13()):1887831 doi:10.3389/fmed.2026.1887831.

    PMID: 42718441
  69. 69

    Eosinophilic myocarditis in platelet-derived growth factor receptor α-rearranged myeloid neoplasm with central nervous system involvement: a case report.

    Aloini MC, Segreti A, Melfi R, Grigioni F

    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 2026; doi:10.4081/monaldi.2026.4166.

    PMID: 42948984